

## DAFTAR PUSTAKA

1. Liuzzo G, Pedicino D, Crea F. Pathophysiology of Acute Coronary Syndrome; In : Camm AJ, Luscher TF, Maurer G, Serruys PW, The ESC Textbook of Cardiovascular Medicine. Third edition. Oxford University Press; 2020: 1222-9.
2. Kurup R, Patel S. Neutrophils in acute coronary syndrome. *European Medical Journal Cardiology*. 2017;5(1):79-87
3. Kumar V, Sharma A, Kumar T, Nath RK. Large Intracoronary Thrombus and its Management During Primary PCI. *Indian Heart Journal*. 2020;72(6):508-16
4. Kotapati VSK, Jyotsna M, Lalita NJ. Coronary Thrombus. *Indian Journal of Cardiovascular Disease in Women*. 2017;2(03):e10-e20.
5. Carter AM. Inflammation, thrombosis and acute coronary syndromes. *Diabetes and Vascular Disease Research*. 2005;2(3):113-21.
6. Oikonomou E, Leopolou M, Theofilis P, Antonopoulos AS, Siasos G, Latsios G, et al. A link between inflammation and thrombosis in atherosclerotic cardiovascular diseases: Clinical and therapeutic implications. *Atherosclerosis*. 2020;309:16-26.
7. Özkan U, Gürdoğan M, Öztürk C, Demir M, Akkuş ÖF, Yılmaz E, et al. Systemic Immune-Inflammation Index: A Novel Predictor of Coronary Thrombus Burden in Patients with Non-ST Acute Coronary Syndrome. *Medicina*. 2022;58(2):143.
8. Badimon L, Vilahur G. Atherosclerosis and thrombosis. In : Tubaro M, Vranckx P, Price S, Vrints C, Bonnefoy E. *The ESC Textbook of Intensive and Acute Cardiovascular Care*: Oxford; 2021;36:447-57
9. Esenboğa K, Kurtul A, Yamantürk YY, Tan TS, Tutar DE. Systemic immune-inflammation index predicts no-reflow phenomenon after primary percutaneous coronary intervention. *Acta Cardiologica*. 2021:1-8.
10. Fuster V, Harrington RA, Narula J, Eapen ZJ. *Atherothrombosis : Disease Burden, Activity, and Vulnerability*. Hurst's the Heart, 14th Ed. McGraw-Hill Education. 2017;32:871-91.
11. Brown DL, Sodhi N. Pathophysiology of Acute Coronary Syndrome : Plaque Rupture and Atherothrombosis. In : *Cardiac Intensive Care*. Elsevier Health Sciences; 2018;7:68-80
12. Mezger M, Nording H, Sauter R, Graf T, Heim C, Von Bubnoff N, et al. Platelet and immune responses during thromboinflammation. *Frontiers in Immunology*. 2019;10:1731.
13. Koupenova M, Kehrel BE, Corkrey HA, Freedman JE. Thrombosis and Platelet: an update. *European Heart Journal*. 2017;38(11):785-91.
14. Fuentes E, Moore-Carrasco R, de Andrade Paes AM, Trostchansky AJ. Role of thrombotic activation and oxidative stress in the evolution of myocardial infarction. *Journal of Cardiovascular Pharmacology and Therapeutics*. 2019;24(6):509-20.
15. Dominick, Angiolillo, Franchi F. Overview of Antiplatelet Therapy for Myocardial Infarction. In : Morrow DA. *Myocardial Infarction: A*

Companion to Braunwald's Heart Disease: Elsevier Health Sciences; 2016:221-37.

16. Wang H, Liu Z, Shao J, Lin L, Jiang M, Wang L, et al. Immune and inflammation in acute coronary syndrome: molecular mechanisms and therapeutic implications. *Journal of Immunology research*; 2020.
17. Palasubramaniam J, Wang X, Peter K. Myocardial infarction—From atherosclerosis to thrombosis: Uncovering new diagnostic and therapeutic approaches. *Arteriosclerosis, Thrombosis, and Vascular Biology*. 2019;39(8):e176-e85
18. Maréchal P, Tridetti J, Nguyen M-L, Wéra O, Jiang Z, Gustin M, et al. Neutrophil Dynamics in Acute Coronary Syndrome. *Journal of clinical medicine*. 2020.
19. Biasucci LM, La Rosa G, Pedicino D, D'Aiello A, Galli M, Liuzzo GJ. Where does inflammation fit? 2017;19(9):1-10.
20. Ambrose JA, Bhullar AS. Inflammation and thrombosis in coronary atherosclerosis: Pathophysiologic mechanisms and clinical correlations. *European Medical Journals*. 2019;4(1):71-8..
21. Stark K, Massberg SJ. Interplay between inflammation and thrombosis in cardiovascular pathology. *Nature Review Cardiology*. 2021;18(9):666-82.
22. Duman H, Çetin M, Durakoğlugil ME, Değirmenci H, Hamur H, Bostan M, et al. Relation of angiographic thrombus burden with severity of coronary artery disease in patients with ST segment elevation myocardial infarction. *Clinical research*. 2015;21:3540.
23. Tanboga IH, Topcu S, Aksakal E, Kalkan K, Sevimli S, Acikel MJC, et al. Determinants of angiographic thrombus burden in patients with ST-segment elevation myocardial infarction. *Clinical and Applied Thrombosis/hemostasis*. 2014;20(7):716-22.
24. Alkarithi G, Duval C, Shi Y, Macrae FL, Ariëns RA. Thrombus structural composition in cardiovascular disease. *Arteriosclerosis, thrombosis, and vascular biology*. 2021;41(9):2370-83.
25. Yamashita A, Asada Y. Pathophysiology of Atherothrombosis—Thrombus Growth, Vascular Thrombogenicity, and Plaque Metabolism. *Thrombosis, Atherosclerosis and Atherothrombosis-New Insights and Experimental Protocols: IntechOpen*; 2015.
26. Kumar V, Sharma AK, Kumar T, Nath RK. Large intracoronary thrombus and its management during primary PCI. *Indian Heart Journal*. 2020;72(6):508-16.
27. Ren H, Zheng Y, Hu X, Yang Y, Zhang Y, Sun Y, et al. High thrombus burden: a review of mechanisms and treatments. *International Journal of Clinical and experimental Medicine*. 2019;12(11):13068-78.
28. Scarparo P, van Gameren M, Wilschut J, Daemen J, Den Dekker WK, Zijlstra F, et al. Impact of thrombus burden on long-term clinical outcomes in patients with either anterior or non-anterior ST-segment elevation myocardial infarction. *Journal of Thrombosis and Thrombolysis*. 2022;54(1):47-57.
29. Yang YL, Wu CH, Hsu PF, Chen SC, Huang SS, Chan WL, et al. Systemic immune-inflammation index (SII) predicted clinical outcome in patients with coronary artery disease. *European Journal of Clinical Investigation*. 2020;50(5):e13230.

30. Pasalic L, Wang SS, Chen VM, editors. Platelets as biomarkers of coronary artery disease. *Seminars in thrombosis and hemostasis*; 2016.
31. Kounis NG, Soufras GD, Tsigkas G, Hahalis GJC. White blood cell counts, leukocyte ratios, and eosinophils as inflammatory markers in patients with coronary artery disease. *Clinical and Applied Thrombosis/hemostasis*. 2015;21(2):139-43.
32. Rosales CJ. Neutrophil: a cell with many roles in inflammation or several cell types?. *Frontiers in Physiology*. 2018;9:113.
33. Kapoor S, Opneja A, Nayak L. The role of neutrophils in thrombosis. *Thrombosis Research*. 2018;170:87-96.
34. Stakos DA, Kambas K, Konstantinidis T, Mitroulis I, Apostolidou E, Arelaki S, et al. Expression of functional tissue factor by neutrophil extracellular traps in culprit artery of acute myocardial infarction. *European Heart Journal*. 2015;36(22):1405-14.
35. Noubouossie DF, Reeves BN, Strahl BD. Neutrophils: back in the thrombosis spotlight. *The Journal of the American Society of Hematology* 2019;133(20):2186-97.
36. Iba T, Levy J. Inflammation and thrombosis: roles of neutrophils, thrombocytes and endothelial cells and their interactions in thrombus formation during sepsis. *Journal of Thrombosis and Hemostasis*. 2018;16(2):231-41.
37. Flego D, Liuzzo G, Weyand CM. Adaptive immunity dysregulation in acute coronary syndromes: from cellular and molecular basis to clinical implications. *Journal of American College of Cardiology*. 2016;68(19):2107-17.
38. Wang Y, Xie Y, Ma H, Su S, Wang J, et al. Regulatory T lymphocytes in myocardial infarction: a promising new therapeutic target. *International Journal of Cardiology*. 2016;203:923-8.
39. Núñez J, Miñana G, Bodí V, Núñez E, Sanchis J, Husser O, et al. Low lymphocyte count and cardiovascular diseases. *Current medicinal chemistry*. 2011;18(21):3226-33.
40. Yilmaz M, Tenekecioglu E, Arslan B, Bekler A, Ozluk OA, Karaagac K, et al. White Blood Cell Subtypes and Neutrophil-Lymphocyte Ratio in Prediction of Coronary Thrombus Formation in Non-ST-Segment Elevated Acute Coronary Syndrome. *Clinical and Applied Thrombosis/hemostasis*. 2015;21(5):446-52.41.
41. Khalfallah M, Maria DA, Allaithy AJ. Impact of Stress Hyperglycemia on No-Reflow Phenomenon in Patients with ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. 2022;17(1)
42. Sigirci S, Yildiz SS, Keskin K, Cetinkal G, Aksan G, Gürdal A, et al. The predictive value of stress hyperglycemia on thrombus burden in nondiabetic patients with st-segment elevation myocardial infarction. 2019;30(6):270-6.
43. Zipes DP, Libby P, Bonow RO, Mann DL, Tomaselli GF, Braunwald E. *Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine*: Elsevier; 2018.
44. D'Onofrio N, Sardu C, Paolisso P, Minicucci F, Gragnano F, Ferraraccio F, et al. MicroRNA-33 and SIRT1 influence the coronary thrombus burden in hyperglycemic STEMI patients. 2020;235(2):1438-52.

45. Chu J, Tang J, Lai Y, Gao Y, Ye Z, Guan C, et al. Association of stress hyperglycemia ratio with intracoronary thrombus burden in diabetic patients with ST-segment elevation myocardial infarction. *Journal of Thoracic Disease*.2020;12(11):6598.
46. Khalfallah M, Maria DA, Allaithy AJ. Impact of Stress Hyperglycemia on No-Reflow Phenomenon in Patients with ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. *Global heart Journal*. 2022;17(1).
47. Li X, Weber NC, Cohn DM, Hollmann MW, DeVries JH, Hermanides J, et al. Effects of Hyperglycemia and Diabetes Mellitus on Coagulation and Hemostasis. *Journal of Clinical medicine*. 2021;10(11):2419.
48. Lemkes BA, Hermanides J, DeVries JH, Holleman F, Meijers JC, Hoekstra J, et al. Hyperglycemia: a prothrombotic factor?. *Journal of Thrombosis and Haemostasis*. 2010;8(8):1663-9.
49. Iwakura K. Stress hyperglycemia and microvascular obstruction after acute myocardial infarction. *Journal of Cardiology*. 2015;65(4):270-1.
50. Undas A, Wiek I, Stępien E, Zmudka K, Tracz W. Hyperglycemia is associated with enhanced thrombin formation, platelet activation, and fibrin clot resistance to lysis in patients with acute coronary syndrome. *American Diabetes Association*. 2008; 31(8):1590-5.
51. Dolu AK, Karayiğit O, Ozkan C, Çelik MC, Kalçık MJ. Relationship between intracoronary thrombus burden and systemic immune-inflammation index inpatients with ST-segment elevation myocardial infarction. *Acta Cardiologica*.2022;1-8.
52. Budzianowski J, Pieszko K, Burchardt P, Rzeźniczak J, Hiczekiewicz J. The role of hematological indices in patients with acute coronary syndrome. *Disease marker*.2017.
53. Zhang C, Liu H, Wang H, Tao Q, Lin X, Ge S, et al. The Predictive Value of Potential Hematological Biomarkers in Acute Coronary Syndrome. *Clinical Laboratory*.2019;65(10).
54. Nozari Y, Geraiely B, Kassaian SE, Saroukhani S, Mortazavi S. The Association Between Modified Intracoronary Thrombus Grade and Cardiovascular Risk Factors and Initial Laboratory Findings in Patients Undergoing Primary Percutaneous Coronary Intervention. *Critical Pathway in Cardiology*. 2019;18(3):135-8.
55. Liu Z, Li D, Xu Y, Xu L, Li J, Liu R, et al. Association between circulating levels of P-selectins and burden of thrombus formation in patients with ST elevation acute myocardial infarction. *African journal of biotechnology*.2010;9(25):3932-7.

Karauzum K, Karauzum I, Hanci K, Gokcek D, Gunay B, Bakhshian H, et al. The Systemic Immune-Inflammation Index May Predict the Coronary Slow Flow Better Than High-Sensitivity C-Reactive Protein in Patients Undergoing Elective Coronary Angiography. 2022.